Literature DB >> 7356347

Disabling pansclerotic morphea of children.

J L Diaz-Perez, S M Connolly, R K Winkelmann.   

Abstract

Fourteen children with generalized morphea involving all levels of the skin and soft tissues were examined. The term "acral pansclerotic morphea" describes the distribution and the multiple levels of sclerosis. Lymphocytic inflammation and hyaline pannicultitis were observed on biopsy specimens in some cases. Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia. Pulmonary changes in five patients and esophageal changes in one imply that acral pansclerotic morphea may be assoicated with mild nonprogressive visceral change. Although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea has been found.

Entities:  

Mesh:

Year:  1980        PMID: 7356347

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  12 in total

Review 1.  Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.

Authors:  Han Jie Soh; Courtney Samuel; Victoria Heaton; William Douglas Renton; Angela Cox; Jane Munro
Journal:  Rheumatol Int       Date:  2019-03-05       Impact factor: 2.631

2.  Squamous cell carcinoma and eosinophilia in a long-term course of pansclerotic morphea.

Authors:  Inderjote Grewal; Omar Khan; William Davis
Journal:  BMJ Case Rep       Date:  2014-10-13

Review 3.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.

Authors:  Andrew Kim; Nicholas Marinkovich; Rebecca Vasquez; Heidi T Jacobe
Journal:  J Rheumatol       Date:  2013-12-01       Impact factor: 4.666

5.  Resolution of pansclerotic morphea after treatment with antithymocyte globulin.

Authors:  Philip Song; Christopher Gocke; Fredrick M Wigley; Francesco Boin
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

6.  Pansclerotic morphea in childhood: a case report.

Authors:  T Doede; U Wollina; W Hindermann; F Schier; M Bondartschuk
Journal:  Pediatr Surg Int       Date:  2003-06-21       Impact factor: 1.827

Review 7.  Overview of Juvenile localized scleroderma and its management.

Authors:  Suzanne C Li; Rong-Jun Zheng
Journal:  World J Pediatr       Date:  2019-11-30       Impact factor: 2.764

8.  Clinical Usefulness of Magnetic Resonance Imaging in Four Children With Scleroderma.

Authors:  Kazushi Agata; Hisashi Kawashima; Atsushi Kumada; Yasuyo Kashiwagi; Hiroko Hara
Journal:  Arch Rheumatol       Date:  2017-11-02       Impact factor: 1.472

Review 9.  UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review.

Authors:  Frank Breuckmann; Thilo Gambichler; Peter Altmeyer; Alexander Kreuter
Journal:  BMC Dermatol       Date:  2004-09-20

10.  Disabling pansclerotic morphea of childhood with extracutaneous manifestations.

Authors:  Mahendra M Kura; Saurabh R Jindal
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.